ERBB2 and neoplasm: Conventional HER2-directed treatments, such as trastuzumab, exert their effects through mechanisms like antibody-dependent cellular cytotoxicity (ADCC), where antibodies bind to HER2 on tumour cells and recruit immune cells to induce cell death.